LOGIN  |  REGISTER
Astria Therapeutics
Assertio

BioCryst Pharmaceuticals to Present at Upcoming Investor Conferences

May 07, 2024 | Last Trade: US$7.40 0.18 2.49

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:

  • Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET.
  • 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET.
  • Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday, May 20, 2024, at 10:30 a.m. ET.
  • Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024, at 9:30 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Contact:
John Bluth
+1 919 859 7910
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page